InterWest Venture Management’s Cidara Therapeutics CDTX Stock Holding History

InterWest Venture Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-67,841	Closed	-$2.74M	–	11
2021 Q2	$2.74M	Hold	67,841	–	–	0.86%	7
2021 Q1	$3.61M	Hold	67,841	–	–	0.95%	8
2020 Q4	$2.71M	Hold	67,841	–	–	0.34%	9
2020 Q3	$3.87M	Hold	67,841	–	–	1.12%	8
2020 Q2	$5.01M	Hold	67,841	–	–	4.15%	5
2020 Q1	$3.37M	Hold	67,841	–	–	3.55%	6
2019 Q4	$5.21M	Hold	67,841	–	–	2.25%	7
2019 Q3	$2.71M	Hold	67,841	–	–	1.04%	9
2019 Q2	$2.28M	Hold	67,841	–	–	0.74%	10
2019 Q1	$3.6M	Hold	67,841	–	–	3.3%	8
2018 Q4	$3.19M	Hold	67,841	–	–	4.48%	7
2018 Q3	$5.97M	Hold	67,841	–	–	2.92%	9
2018 Q2	$7.05M	Hold	67,841	–	–	2.98%	7
2018 Q1	$5.43M	Hold	67,841	–	–	2.29%	8
2017 Q4	$9.23M	Hold	67,841	–	–	3.15%	7
2017 Q3	$11M	Hold	67,841	–	–	2.86%	6
2017 Q2	$10.2M	Hold	67,841	–	–	2.41%	7
2017 Q1	$10.6M	Hold	67,841	–	–	2.25%	6
2016 Q4	$14.1M	Buy	+67,841	New	+$14.1M	3.36%	6

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

InterWest Venture Management's CDTX Position: Q3 2021 in Review

InterWest Venture Management sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 67,841 shares — an estimated $2.74M sold.

InterWest Venture Management first reported a position in CDTX in Q4 2016 and held it in 19 quarters. The position peaked at $14.1M in Q4 2016. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

InterWest Venture Management reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
InterWest Venture Management sold 67,841 Cidara Therapeutics shares in Q3 2021, an estimated $2.74M.
InterWest Venture Management first reported a position in Cidara Therapeutics in Q4 2016 and held it in 19 quarters.
InterWest Venture Management's Cidara Therapeutics position peaked at $14.1M in Q4 2016.
50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on InterWest Venture Management's 13F filing for Q3 2021, filed 19 Oct 2021.